Cellectis (NASDAQ:CLLS) Upgraded at StockNews.com

StockNews.com upgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a buy rating in a research note released on Monday.

Cellectis Stock Performance

NASDAQ:CLLS opened at $1.26 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. Cellectis has a fifty-two week low of $1.14 and a fifty-two week high of $3.38. The firm has a market cap of $70.04 million, a PE ratio of -0.97 and a beta of 3.21. The business has a 50 day moving average price of $1.41 and a 200-day moving average price of $1.72.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $33.22 million for the quarter, compared to analysts’ expectations of $5.90 million. Equities research analysts predict that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

Institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in shares of Cellectis during the fourth quarter valued at approximately $962,000. Wells Fargo & Company MN boosted its holdings in Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 12,500 shares in the last quarter. Finally, B Group Inc. purchased a new position in Cellectis during the 4th quarter valued at $5,547,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.